Vascular Inflammation in Psoriasis - Extension Study
Status:
Completed
Trial end date:
2016-10-27
Target enrollment:
Participant gender:
Summary
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects
of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained
improvement in vascular inflammation, lipid metabolism, and inflammatory markers. VIP-E
extends VIP study procedures for 40-52 weeks including questionnaires, physical exams, blood
and urine samples, lab tests, one additional FDG-PET/CT scan, and adalimumab injections
following FDA-approved psoriasis treatment regimen.